Page 93 - Read Online
P. 93

Potdar. J Cancer Metastasis Treat 2020;6:38  I  http://dx.doi.org/10.20517/2394-4722.2020.75                                Page 3 of 3

               Assessment of Chronic Illness Therapy (FACIT) item library with patient-reported adverse events
               associated with immune checkpoint modulators (ICM). This FACIT item library will allow clinicians
               to monitor the value of ICM treatment for patients with cancer by looking at the clinically relevant
               measurement of symptoms. Thus, the use of item selection from FACIT item library will be encouraged in
               clinical research and clinical practice evaluations.


               We are fortunate to obtain a very interesting review article on immune checkpoint inhibitor therapy
               in EBV-associated Gastric Cancer (EBVaGC) from Dr. Frank J. Slack from Beth Israel Deaconess
               Medical Centre, Harvard Medical School, Boston, USA. Several studies have shown that EBVaGC is
               commonly characterized by high lymphocytic infiltration in the tumor microenvironment, coupled with
               overexpression of immune checkpoint-related genes, including PD-L1. However, the regulation of PD-L1
               expression in EBVaGC is poorly understood and further studies are needed to explain how EBV and host
               factors contribute to it. Dr. Slack highlighted that EBVaGC is a strong candidate for immune checkpoint
               blockade therapy after proper research in this area.


               Thus, overall, we have to state here that this special issue on Immunotherapy of Cancer has included a
               number of original research articles, clinical studies, and systematic reviews of cancer immunotherapy
               from different angles contributed by various distinguished scientists and clinicians from prime institutes
               and medical centers all over the world. We hope that this special issue can provide valuable information to
               cancer researchers, clinicians, and academic professors for the enhancement of knowledge in the field of
               immunotherapy as well as better therapy of metastatic cancers.


               DECLARATIONS
               Acknowledgments
               We would like to thank all the authors of this special issue for their excellent research stories and
               stimulating ideas. We would also like to express our great appreciation to all the special issue reviewers and
               editors, whose efforts substantially contributed to the improvement of the overall quality of this issue.

               Authors’ contributions
               Wrote and reviewed the manuscript: Potdar PD


               Availability of data and materials
               Not applicable.

               Financial support and sponsorship
               None.


               Conflicts of interest
               The author declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2020.
   88   89   90   91   92   93   94   95   96   97   98